May 7, 2018
TOKYO, JAPAN - May 7, 2018 - Terumo Corporation (TSE: 4543) today announced that it concluded an agreement with U.S.-based DexCom, Inc. ("Dexcom") to distribute the company's Continuous Glucose Monitoring (CGM) devices exclusively in Japan, with sales to begin in the fiscal year ending March 31, 2019 (FY2018). The goal is to gradually launch new products over the next few years, including next generation Dexcom CGM systems such as the G6 and additional platforms in Dexcom's pipeline. Henceforth, Terumo is also considering a collaboration to integrate CGM with an insulin pump platform.
Dexcom's system is the global market leader in real-time CGM. The products are equipped with a safety mechanism that automatically issues an alert when blood glucose is low or high.
Terumo has been selling medical devices for diabetes for over 30 years. The company recently achieved a significant milestone in this category, selling over one billion of the world's thinnest pen needle for insulin use, which Terumo launched in 2005. In the fiscal year 2018, Terumo plans to launch Japan's first tubing-free insulin patch pump.
Through this collaboration with Dexcom, Terumo will expand its product lineup and will continue to provide products and services that improve quality of life for people with diabetes.
CGM stands for continuous glucose monitoring or continuous glucose monitors. It is a system that measures glucose concentration in the interstitial fluid of people with diabetes and shows the glucose reading, rate of change and trends. For patients and healthcare providers, knowing the blood glucose level and controlling it in a normal range is an important factor in diabetes treatment. Usually, blood glucose levels are controlled based on the numbers from blood tests or self-blood glucose monitoring. The use of CGM, which measures glucose continuously, makes it easy to determine blood glucose level trends and standards. This is expected not only to reduce hypoglycemia risk but also to be useful in determining treatment courses.
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers, with over $5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician-office use. Terumo contributes to society by providing valued products and services to the health care market, and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.
(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.